MINT-CIPROFLOX TABLET

Land: Canada

Sprog: engelsk

Kilde: Health Canada

Aktiv bestanddel:

CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE)

Tilgængelig fra:

MINT PHARMACEUTICALS INC

ATC-kode:

J01MA02

INN (International Name):

CIPROFLOXACIN

Dosering:

500MG

Lægemiddelform:

TABLET

Sammensætning:

CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE) 500MG

Indgivelsesvej:

ORAL

Enheder i pakken:

100

Recept type:

Prescription

Terapeutisk område:

QUINOLONES

Produkt oversigt:

Active ingredient group (AIG) number: 0123207001; AHFS:

Autorisation status:

APPROVED

Autorisation dato:

2014-05-15

Produktets egenskaber

_ MINT-CIPROFLOX _
_Page _
_1_
_ of _
_62_
_ _
_ _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
MINT-CIPROFLOX
Ciprofloxacin Tablets
Tablets, 500 mg and ciprofloxacin (as ciprofloxacin hydrochloride),
Oral
British Pharmacopoeia (BP)
Antibacterial Agent
Mint Pharmaceuticals Inc.
6575 Davand Drive
Mississauga, ON, L5T 2M3
Date of Initial Authorization:
MAY 15, 2014
Date of Revision:
AUG 22, 2022
Submission Control Number: 262485
_ MINT-CIPROFLOX _
_Page _
_2_
_ of _
_62_
_ _
_ _
RECENT MAJOR LABEL CHANGES
2 CONTRAINDICATIONS
08/2022
4 DOSAGE AND ADMINISTRATION, 4.5 MISSED DOSE
08/2022
7 WARNINGS AND PRECAUTIONS
09/2020
TABLE OF CONTENTS
Sections or subsections that are not applicable at the time of
authorization are not listed.
RECENT MAJOR LABEL
CHANGES………………………………………………………………………………………………2
TABLE OF
CONTENTS…………………………………………………………………………………………………………………2
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................................
4
1. INDICATIONS
......................................................................................................................
4
1.1 Pediatrics
...............................................................................................................................
7
1.2 Geriatrics
...............................................................................................................................
7
2. CONTRAINDICATIONS
.........................................................................................................
7
3. SERIOUS WARNINGS AND PRECAUTIONS BOX
.....................................................................
8
4. DOSAGE AND ADMINISTRATION
.........................................................................................
8
4.1 Dosing
Considerations.....................................................................................